Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
Prnewswire·2025-11-27 16:49Accessibility StatementSkip Navigation BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code:Â GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore its potential to mainta ...